Previous 10 | Next 10 |
The FDA's Oncologic Drugs Advisory Committee will meet on Thursday, August 13, to review and discuss Mesoblast Limited's ( MESO +5.9% ) marketing application for Ryoncil (remestemcel-L) for the treatment of children with steroid-refractory acute graft versus host disease (GvHD). M...
Investment Thesis I first learned of remestemcel-l (labeled Prochymal at that time) over 10 years ago, I remember my response well, new products take years! But I followed Osiris Therapeutics in its development. This lead me to Mesoblast after it acquired remestemcel-l and associated i...
It's not uncommon for inexperienced investors to go through a penny stock phase. The rationale is understandable: You can own hundreds or thousands of shares of a company that trades for a few cents a pop. It seems like a great deal, especially in the dreamy scenario where the stock appre...
Shares of Mesoblast (NASDAQ: MESO) rose as much as 18.1% today after the company announced its experimental stem cell treatment, remestemcel-L, will be available under an expanded-access protocol for children with COVID-19 in the United States. More specifically, the company filed the...
LM Funding America (NASDAQ: LMFA ) +83% . More news on: LM Funding America, Inc., Myomo, Inc., Electrameccanica Vehicles Corp., Stocks on the move, , Read more ...
Mesoblast (NASDAQ: MESO ) initiates an expanded access protocol (EAP) in the U.S. for compassionate use of its allogeneic mesenchymal stem cell product candidate, remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisy...
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the trea...
Cytodyn ( OTCQB:CYDY ) is a triple threat or more with one drug, leronlimab. HIV First, is its work on HIV over the past years. Over 800 patients were tested, and since it blocks the CCR5 receptor which is HIV’s known point of entry, it works very well. A BLA (biologics license ap...
When doctors, researchers, and politicians discuss the trajectory of the coronavirus pandemic, the most hopeful scenarios include the development of successful treatments and vaccines that make the disease burden more manageable and ultimately squash it for good. Hundreds of drug compounds are b...
Sintx Technologies (NASDAQ: SINT ) -11% . More news on: Sintx Technologies, Inc., Sierra Metals Inc., Hertz Global Holdings, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...